Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia

[11] Riviere I(2015)Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia OncoImmunology 4 e1027469-undefined

[12] Wang X(2016)CD19 CAR-T cells of defined CD4 J Clin Investig 126 6-undefined

[13] Brentjens RJ(2016):CD8 Sci Transl Med 8 355ra116-undefined

[14] Davila ML(2015) composition in adult B cell ALL patients J Clin Oncol 33 540-undefined

[15] Riviere I(2017)Immunotherapy of non-Hodgkin lymphoma with a defined ratio of CD8 J Clin Oncol 35 3010-undefined

[16] Till BG(2015) and CD4 Sci Transl Med 371 1507-undefined

[17] Jensen MC(2017) CD19-specific chimeric antigen receptor-modified T cells J Clin Oncol 6 224ra25-undefined

[18] Wang J(2014)Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor N Engl J Med 6 664-undefined

[19] Lee DW(2014)Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib Sci Transl Med 341 418-undefined

[20] Kochenderfer JN(2016)Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia Cancer Discovery 23 464-undefined

[11] Riviere I(2015)Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia OncoImmunology 4 e1027469-undefined

[12] Wang X(2016)CD19 CAR-T cells of defined CD4 J Clin Investig 126 6-undefined

[13] Brentjens RJ(2016):CD8 Sci Transl Med 8 355ra116-undefined

[14] Davila ML(2015) composition in adult B cell ALL patients J Clin Oncol 33 540-undefined

[15] Riviere I(2017)Immunotherapy of non-Hodgkin lymphoma with a defined ratio of CD8 J Clin Oncol 35 3010-undefined

[16] Till BG(2015) and CD4 Sci Transl Med 371 1507-undefined

[17] Jensen MC(2017) CD19-specific chimeric antigen receptor-modified T cells J Clin Oncol 6 224ra25-undefined

[18] Wang J(2014)Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor N Engl J Med 6 664-undefined

[19] Lee DW(2014)Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib Sci Transl Med 341 418-undefined

[20] Kochenderfer JN(2016)Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia Cancer Discovery 23 464-undefined